Published Date: 24-01-2018
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report North America Stroke Management Market, published by KBV research, the North America Stroke Management Market would witness market growth of 6.8% CAGR during the forecast period (2018 – 2024).
The US market would dominate the North America Ischemic Stroke Management Market by Country by 2024, growing at a CAGR of 4.3 % during the forecast period. The Canada market is expected to witness a CAGR of 6.8% during (2018 - 2024). Additionally, The Mexico market is expected to witness a CAGR of 6.7% during (2018 - 2024).
The Tissue Plasminogen Activator market dominated the Mexico Stroke Management Market by Therapeutics Type 2017, and would achieve a market value of $167 million by 2024, growing at a CAGR of 8.1 % during the forecast period. The Anticoagulant market is expected to witness a CAGR of 9.9% during (2018 - 2024). Additionally, The Antiplatelet market is expected to witness highest CAGR of 9% during (2018 - 2024).
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of ABBOTT Laboratories, B. Braun Melsungen Ag, Boston Scientific Corporation, Cardinal Health, Inc., Ge Healthcare, Glaxosmithkline Plc, Medtronic Plc., Siemens Aktiengesellschaft, Merck & Co., Inc., and Bristol-Myers Squibb Company.
Unique Offerings from KBV Research